Skip to main content
Premium Trial:

Request an Annual Quote

Namocell, SingLab Technologies Ink Distribution Agreement for Singapore

NEW YORK – Namocell said on Monday that it has signed an agreement with SingLab Technologies to distribute its single-cell isolation systems in Singapore.

The Mountain View, California-based company provides single-cell sorting and dispensing platforms for research and therapeutics development.

"Advances in cell biology have created a new era of cell-based research and therapeutics," said SingLab CEO Michael Choi in a statement. "[Namocell's] benchtop low-pressure single-cell dispensers are designed to protect the viability and integrity of isolated cells for a wide range of downstream applications."

"There has been increasing demand for our single-cell dispenser systems in the Southeast Asia market," Junyu Lin, CEO of Namocell, said in a statement. "[SingLab's] strong technical expertise in cell-based R&D products and excellent customer service capabilities make them a great partner."

Financial terms of the agreement were not disclosed.

In March, Namocell signed an agreement with Germany-based Omni Life Science (OLS) to distribute the firm's single-cell dispensers in Germany and Austria.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.